GB2230527A — 4-(substituted amino)-pyrimidinium derivatives as cardiovascular agents

USPTO Abstract

This invention concerns novel aminopyrimidinium salts of the formula I: <IMAGE> in which R<1> is alkyl, alkenyl, cycloalkyl, phenyl, phenylalkyl or cycloalkyl-alkyl; one of R<2> and R<6> is a basic group selected from amino, alkylamino, dialkylamino of up to eight carbon atoms, pyrrolidino, piperidino and morpholino; and the other of R<2> and R<6> is hydrogen, alkyl, alkenyl, alkoxyalkyl, phenyl, phenylalkyl, cycloalkyl or cycloalkyl-alkyl; or both of R<2> and R<6> are basic groups as mentioned above; and R<5> is hydrogen, (1-4C)alkyl or (3-6C) alkenyl; or R<2> is a basic group as mentioned above, and R<5> and R<6> together form alkylene or, together with the appendant carbon atoms of the pyrimidine ring, complete a benzene ring; R<4> is hydrogen, alkyl, cycloalkyl-alkyl, alkenyl, alkynyl or phenylalkyl; or R<4> is an optionally substituted alkylene or alkenylene linked to the nitrogen atom of the group Q.A.N-, either of which linking groups may thereby completing a ring including two adjacent carbon atoms of Q, the carbon atoms of A and the adjacent nitrogen atom of the group -A.N-; A is a direct bond to the group -N(R<4>)- or is alkylene or oxyalkylene; Q is a pyridyl, furyl, thienyl or phenyl moiety; and Y is a physiologically acceptable anion; but excluding a number of compounds specified hereinafter. The invention also includes certain closely related anhydro-base derivatives which, like the formula I compounds, possess beneficial effects on the cardiovascular system (and in particular beneficial effects modulated via the sino-atrial node). Also included are pharmaceutical compositions containing the formula I compound (or a related anhydro-base) as active ingredient, and processes for the manufacture of the various novel compounds.